Related Experiment Video

Updated: Jun 12, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Chemotherapy resistance abrogation in metastatic melanoma

Hussein A Tawbi1, Shama C Buch

  • 1University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, USA. tawbhx@upmc.edu

Clinical Advances in Hematology & Oncology : H&O
|May 28, 2010
PubMed

Insights

Melanoma incidence is rising, but effective treatments lag. DNA repair mechanisms enable tumor resistance to chemotherapy, highlighting them as targets for new melanoma therapies.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Melanoma incidence is increasing globally, with limited advances in survival-improving therapies.
  • Current chemotherapy for metastatic melanoma, primarily alkylating agents, shows low response rates due to tumor resistance.
  • DNA repair pathways are key mechanisms enabling cancer cells to survive chemotherapy-induced damage.

Purpose of the Study:

  • To review the role of dysregulated DNA repair pathways in melanoma chemotherapy resistance.
  • To explore the potential of targeting DNA repair mechanisms for novel therapeutic strategies in melanoma.

Main Methods:

  • Literature review of current knowledge on DNA repair in melanoma.
  • Analysis of studies on novel agents targeting DNA repair pathways.
  • Examination of combination therapies involving DNA repair inhibitors and cytotoxic agents.

Main Results:

  • Dysregulation of DNA repair pathways contributes significantly to chemotherapy resistance in melanoma.
  • Novel agents targeting DNA repair show promise, but success varies.
  • Combination strategies are being explored to overcome resistance.

Conclusions:

  • Targeting DNA repair pathways represents a promising avenue for developing more effective melanoma treatments.
  • Further research into the specific mechanisms of DNA repair dysregulation and targeted therapies is warranted.
  • Developing novel therapeutics that abrogate DNA repair could improve outcomes for patients with metastatic melanoma.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.